ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
8.40
+0.15 (1.82%)
At close: Aug 27, 2026, 4:00 PM EDT
8.41
+0.01 (0.12%)
After-hours: Aug 27, 2026, 7:59 PM EDT
ImmunityBio Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 164.89 | 112.98 | 14.15 | - | - | 0.93 |
Other Revenue | 0.9 | 0.31 | 0.6 | 0.62 | 0.24 | - |
| 165.79 | 113.29 | 14.75 | 0.62 | 0.24 | 0.93 | |
Revenue Growth | 192.92% | 668.32% | 2270.58% | 159.17% | -74.30% | 54.38% |
Cost of Revenue | 1.1 | 0.75 | - | - | - | - |
Gross Profit | 164.7 | 112.54 | 14.75 | 0.62 | 0.24 | 0.93 |
Selling, General & Admin | 172.6 | 150 | 168.78 | 129.62 | 108.71 | 126.76 |
Research & Development | 243.89 | 218.56 | 190.14 | 232.37 | 242.2 | 191.6 |
Operating Expenses | 416.5 | 368.56 | 358.93 | 361.99 | 350.91 | 318.36 |
Operating Income | -251.8 | -256.03 | -344.18 | -361.36 | -350.67 | -317.42 |
Interest Expense | -114.48 | -112.53 | -154.33 | -129.2 | -63.52 | -14.85 |
Interest & Investment Income | 9.83 | 6.41 | 7.98 | 1.13 | - | - |
Earnings From Equity Investments | - | - | - | -7.55 | -12.11 | -0.8 |
Other Non Operating Income (Expenses) | -628.73 | 10.54 | 77.52 | -84.44 | 16.91 | 4.81 |
EBT Excluding Unusual Items | -985.18 | -351.61 | -413.01 | -581.42 | -409.38 | -328.27 |
Merger & Restructuring Charges | - | - | - | - | - | -13 |
Gain (Loss) on Sale of Investments | - | - | -0.63 | -1.59 | -7.28 | -8.72 |
Asset Writedown | - | - | - | -0.89 | -0.68 | - |
Other Unusual Items | -7.4 | - | - | - | 0.05 | 0.14 |
Pretax Income | -992.58 | -351.61 | -413.65 | -583.89 | -417.29 | -349.84 |
Income Tax Expense | -0.16 | -0.14 | - | -0.04 | 0.03 | 0.01 |
Earnings From Continuing Operations | -992.42 | -351.47 | -413.65 | -583.85 | -417.32 | -349.85 |
Minority Interest in Earnings | 0.06 | 0.07 | 0.08 | 0.66 | 0.75 | 3.06 |
Net Income | -992.36 | -351.4 | -413.56 | -583.2 | -416.57 | -346.79 |
Net Income to Common | -992.36 | -351.4 | -413.56 | -583.2 | -416.57 | -346.79 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 1,004 | 920 | 697 | 509 | 400 | 389 |
Shares Outstanding (Diluted) | 1,004 | 920 | 700 | 509 | 400 | 389 |
Shares Change | 26.61% | 31.33% | 37.71% | 27.19% | 2.74% | 3.23% |
EPS (Basic) | -0.99 | -0.38 | -0.59 | -1.15 | -1.04 | -0.89 |
EPS (Diluted) | -0.99 | -0.38 | -0.62 | -1.15 | -1.04 | -0.89 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -288.07 | -308.78 | -398.12 | -397.34 | -415.67 | -307.98 |
Free Cash Flow Per Share | -0.29 | -0.34 | -0.57 | -0.78 | -1.04 | -0.79 |
Gross Margin | 99.34% | 99.33% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -151.88% | -226.00% | -2334.23% | -58097.11% | -146111.67% | -33985.44% |
Profit Margin | -598.55% | -310.18% | -2804.77% | -93761.41% | -173569.58% | -37129.55% |
Free Cash Flow Margin | -173.76% | -272.56% | -2700.06% | -63881.19% | -173196.25% | -32974.52% |
EBITDA | -235.3 | -240.6 | -326.63 | -342.85 | -332.41 | -303.19 |
EBITDA Margin | -141.92% | -212.38% | - | - | - | - |
D&A For EBITDA | 16.5 | 15.43 | 17.55 | 18.51 | 18.26 | 14.24 |
EBIT | -251.8 | -256.03 | -344.18 | -361.36 | -350.67 | -317.42 |
EBIT Margin | -151.88% | -226.00% | - | - | - | - |
Revenue as Reported | 165.79 | 113.29 | 14.75 | 0.62 | 0.24 | - |